摘要：

The article reports on the approval of opioid medication, called Osolis, by the U.S. Food and Drug Administration (FDA) to relieve severe flare-ups of pain in cancer patients. The drug, developed by Aveva Drug Delivery Systems, delivers the opioid fentanyl via an absorbable film that adheres to the inside of the cheek. It notes that FDA requires safeguards, including distribution limits, to prevent misuse.

展开